Vinu Krishnan, Doctoral Candidate, University of Delaware
Hematologic malignancies, such as leukemia have been studied in great depth at pathological and molecular levels to result in therapeutic advances that attain remission and improve survival in patients subjected to chemotherapy. However, significant proportions of these patients suffer from relapse or treatment related side-effects. This is due to factors that range from drug instability or short half-life to induction of non-specific toxicity. Emerging interest in nanomedicine has resulted in clinical development of 1st generation nanodrugs that have improved pharmacological and therapeutic properties of anticancer drugs. Herein, we engineer and formulate an advanced and novel nanotechnology based drug delivery system that can specifically target and treat leukemia effectively at reduced doses. This could achieve long term implications in sustaining and improving existing remission rates. Based on our preliminary pre-clinical validation; a novel biocompatible platform is established to successfully advance among drug delivery systems of the future to target and treat blood cancers with enhanced efficacy and reduced toxicity.
Chairman Chatter: Embracing the Challenge
Tuesday, 20 Sep 2016 19.09
Women in Pharma Debuts at 2016 ISPE Annual Meeting & Expo
Tuesday, 20 Sep 2016 14.09
You’re All HEROES! Two Powerful Pharma Keynote Messages
Tuesday, 20 Sep 2016 02.09